Imai, Takeharu http://orcid.org/0000-0003-2174-7392
Tanaka, Yoshihiro http://orcid.org/0000-0002-0300-7924
Sato, Yuta
Mase, Junichi
Suetsugu, Tomonari
Fukada, Masahiro
Yasufuku, Itaru
Iwata, Yoshinori
Mori, Ryutaro
Imai, Hisashi
Kato, Takazumi
Okumura, Naoki
Matsuhashi, Nobuhisa
Takahashi, Takao
Futamura, Manabu
Yoshida, Kazuhiro
Article History
Received: 14 December 2020
Accepted: 9 August 2021
First Online: 28 August 2021
Declarations
:
: This study was approved by the review board of the Gifu University Hospital (approval no. 2019-203).
: Informed consent was obtained in the form of opt-out on the website for the publication of this article.
: Dr. Yoshida reports receipt of grants, personal fees, and non-financial support from EA Pharma Co., Ltd., Sanofi, Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., and Novartis Pharma K.K. and grants from Kyowa Hakko Kirin Co., Ltd. outside of the submitted work. Dr. Tanaka reports receipt of grants from Daiichi Sankyo Co., Ltd. outside of the submitted work. Other authors have no conflict of interest to disclose.
Free to read: This content has been made available to all.